FluoGuide A/S (OM: FLUO)
Health Care · Biotechnology · DK
Skr31.10
-1.89% today · -19.7% 1Y
FluoGuide A/S (OM: FLUO) operates in the Biotechnology industry within the Health Care sector. The company is valued at $54.73M and employs 7 people.
Over the last twelve months the share price has lost 19.7%, trading between 28.00 and 47.80.
Tweenvest scores FluoGuide A/S across four factors: quality 25/100, value 19/100. Its strongest factor is quality.
FLUO price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $54.73M
- Revenue (TTM)
- $36.72K
- P/E
- —
- EPS
- -2.88
- Dividend yield
- —
- Beta (5Y)
- 0.42
- 52-week high
- Skr47.80
- 52-week low
- Skr28.00
- Avg volume (3M)
- —
- Shares outstanding
- 16.35M
- Employees
- 7
- Next earnings
- —
About FluoGuide A/S
FluoGuide A/S is a Danish life science company dedicated to developing and commercializing advanced surgical solutions. Its flagship investigational compound, FG001, is currently undergoing Phase I/II clinical trials for the treatment of high-grade glioma (a type of brain cancer) and has also advanced to Phase II development for lung cancer. The company is further developing FG002, a preclinical-stage product that utilizes novel uPAR-targeted luminescent technology to enable surgeons to distinguish cancerous from healthy tissue during operations. FluoGuide A/S has established key collaborations, including an agreement with Linköping University Hospital to support the Phase I/II clinical evaluation of FG001 for the surgical removal of brain tumors, and an ongoing partnership with Copenhagen University Hospital. The company was founded in 2018 and maintains its headquarters in Copenhagen, Denmark.
- ISIN
- DK0061123312
- Founded
- 2018
- Listed since
- Jun 17, 2019
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.